Our HIV research agenda has to address the world outside of a clinical trial, vaccine researcher Stephaun E. Wallace, Ph.D., argues.
HIV vaccine researchers are working to study and solve the problem, with a focus on how researchers themselves can more deeply build and earn trust.
A new study demonstrates the phenomenon, but experts say more research needs to determine why it occurs -- and what researchers can do differently to reduce it.
April 4, 2019: what’s driving the HIV outbreak in northeastern Massachusetts; race-gender HIV disparities among Baltimore sex workers; high PrEP interest, low awareness among southern black women; naltrexone implants for opioid dependence.
As the 2019 National HIV Prevention Conference kicked off on March 18, plenary speakers discussed not only recent biomedical advances, but also what is truly needed in heavily affected U.S. communities to end the epidemic.
This study shows that with the right supportive services, black men who have sex with men will use pre-exposure prophylaxis (PrEP), and with very high adherence.
Some have expressed concern that, as PrEP use increases in the U.S., so will the transmission of other STIs. A new study pushes back against that worry.
Alternate PrEP guideline recommendations; partner notification and onward HIV transmission; shifting causes of death among HIV/HCV-coinfected people; correlates of lower adherence among people on methadone maintenance.
How much of a role do community faith-based public health programs play in reducing the disparity we see among African Americans contracting HIV?